KJHP
REGN icon

K.J. Harrison & Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

K.J. Harrison & Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$406K Sell
526
-5,565
-91% -$4.26M 0.07% 185
2025
Q4 		$4.7M Buy
6,091
+2,000
+49% +$1.36M 0.63% 46
2025
Q3 		$2.45M Buy
4,091
+2,090
+104% +$1.18M 0.35% 79
2025
Q2 		$1.05M Buy
+2,001
New +$1.12M 0.17% 119

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

K.J. Harrison & Partners's REGN Position: Q1 2026 in Review

K.J. Harrison & Partners reduced its Regeneron Pharmaceuticals (REGN) stake by 91% in Q1 2026, selling an estimated $4.26M and leaving 526 shares worth $406K. The position accounts for 0.07% of the portfolio, ranked #185.

K.J. Harrison & Partners first reported a position in REGN in Q2 2025 and has held it in 4 quarters since. The position peaked at $4.7M in Q4 2025. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • K.J. Harrison & Partners held 526 shares of Regeneron Pharmaceuticals worth $406K as of Q1 2026.
  • K.J. Harrison & Partners sold 5,565 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $4.26M.
  • Regeneron Pharmaceuticals made up 0.07% of K.J. Harrison & Partners's portfolio in Q1 2026, its #185 holding.
  • K.J. Harrison & Partners first reported a position in Regeneron Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • K.J. Harrison & Partners's Regeneron Pharmaceuticals position peaked at $4.7M in Q4 2025.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on K.J. Harrison & Partners's 13F filing for Q1 2026, filed 28 Apr 2026.